[{"orgOrder":0,"company":"Aarvik Therapeutics","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aarvik Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aarvik Therapeutics \/ ArriVent","highestDevelopmentStatusID":"14","companyTruncated":"Aarvik Therapeutics \/ ArriVent"}]

Find Clinical Drug Pipeline Developments & Deals by Aarvik Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : ArriVent will be responsible for clinical development and commercialization of a novel ADC molecule, for oncology indications, that relies on the unique modular platform developed by Aarvik.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 15, 2024

                          Lead Product(s) : ADC-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Arrivent

                          Deal Size : $100.0 million

                          Deal Type : Collaboration

                          blank